Biogen Inc logo

Biogen Inc

€ 264.10 (-0.6%) Feb 1
P/E:
14.83
P/B:
3.28
Market Cap:
€ 38.66B ($ 42.61B)
Enterprise V:
€ 40.25B ($ 44.36B)
Volume:
-
Avg Vol (2M):
45.00
Also Trade In:
Volume:
-
Market Cap €:
38.66B
Market Cap $:
42.61B
PE Ratio:
14.83
Avg Vol (2-Month):
45.00
Enterprise Value €:
40.25B
Enterprise Value $:
44.36B
PB Ratio:
3.28

Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Name Current Vs Industry Vs History
Cash-To-Debt 0.74
Equity-to-Asset 0.51
Debt-to-Equity 0.52
Debt-to-EBITDA 1.59
Interest Coverage 11.56
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.16
Distress
Grey
Safe
Beneish M-Score -2.59
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 40.76
9-Day RSI 46.94
14-Day RSI 47.62
6-1 Month Momentum % 24.05
12-1 Month Momentum % 26.33

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.49
Quick Ratio 2.14
Cash Ratio 1.25
Days Inventory 203.01
Days Sales Outstanding 71.1
Days Payable 68.88

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 9.3